Quick Answer
ADIAL PHARMACEUTICALS, INC. reported Net Income Loss of -$7.98 million for the year ending 2025.
- ADIAL PHARMACEUTICALS, INC. showed an increase of +39.6% in Net Income Loss from 2024 to 2025.
- This data is from ADIAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$264.3 thousand | Q3 2017: -$292.6 thousand | Q1 2018: -$379.0 thousand | Q2 2018: -$1.79 million | Q3 2018: -$8.19 million | Q1 2019: -$2.68 million | Q2 2019: -$2.13 million | Q3 2019: -$1.72 million | Q1 2020: -$2.28 million | Q2 2020: -$1.81 million | Q3 2020: -$3.34 million | Q1 2021: -$4.83 million | Q2 2021: -$4.44 million | Q3 2021: -$4.32 million | Q1 2022: -$2.91 million | Q2 2022: -$3.85 million | Q3 2022: -$3.11 million | Q1 2023: -$2.91 million | Q2 2023: $1.09 million | Q3 2023: -$1.38 million | Q1 2024: -$6.48 million | Q2 2024: -$2.46 million | Q3 2024: -$2.19 million | Q1 2025: -$2.23 million | Q2 2025: -$1.96 million | Q3 2025: -$1.79 million.
- Over the full 9 years of available data (2017 to 2025), ADIAL PHARMACEUTICALS, INC.'s Net Income Loss has declined by 600.1%.
- Historical annual values: Fiscal year 2025: -$7.98 million | Fiscal year 2024: -$13.20 million | Fiscal year 2023: -$5.12 million | Fiscal year 2022: -$12.73 million | Fiscal year 2021: -$19.42 million | Fiscal year 2020: -$10.89 million | Fiscal year 2019: -$8.59 million | Fiscal year 2018: -$11.63 million | Fiscal year 2017: -$1.14 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: